Beijing Kayin Technology Co., Ltd (hereinafter referred to as "Kayin Technology") was founded in 2008 with a registered capital of 75.3 million RMB. With biotechnology as its platform, the company focuses on the field of liver disease, and is committed to becoming a specialized public company providing health solutions. 2010 completed the shareholding system restructuring, June 2011 introduced Legend Capital (Junlian Capital), and May 2012 introduced Haitong Kaiyuan and other strategic partners. 2011 was selected as one of the top high-end enterprises in Zhongguancun and one of the top 100 emerging enterprises in Zhongguancun.
The company's R&D team consists of nearly 30 overseas experts, doctors and masters, and is guided by academician Hou Yunde, a famous expert in molecular virology, and the vice president of R&D is Dr. Pan Hai, a senior scientist who used to work for Amgen, the world's largest bio-pharmaceutical company; with the way of integrative innovation, the company has made great progress in the 11th Five-Year Plan, 12th Five-Year Plan, and 12th Five-Year Plan, "Based on the major national scientific and technological projects in the 11th Five-Year Plan and 12th Five-Year Plan, the R&D center will develop a series of innovative drugs with independent intellectual property rights, and establish a series of products with the pattern of antiviral, immunity enhancement, hepatoprotection, anti-fibrotic and hepatocellular carcinoma. The R&D center is the "Beijing Recombinant Protein Drug Engineering and Technology Research Center". At present, the company is carrying out 19 R&D projects, including 6 biologics R&D projects, 7 chemical R&D projects and 6 technology platform projects.
Kain Science and Technology has 7 GMP production workshops for biological products and chemical drugs, and 15 varieties have been listed on the market. Its leading products, recombinant human interferon α2b, have ranked the first in market sales for four consecutive years, compound glycyrrhizin for two consecutive years, and naloxone hydrochloride for four consecutive years, and have been exported to or registered in 13 countries.
Development Goal:
Through concentration and specialization, Kayin Technology will become a leading brand enterprise in the field of liver disease.
The company plans to realize listing in the domestic GEM in 2014, and the market value reaches more than 2 billion yuan.
Culture
Excellence: strive for excellence, excellence above all
Innovation: embrace change, passion for new
Cooperation: deliver results, cooperation wins
Execution: perfect action, win in execution
The company is a leading brand in the field of liver disease through focus and specialization.
Company Vision
Professional Quality and Healthy Life
--With biotechnology as a platform, focusing on the field of liver disease, we are committed to become a specialized public company providing health solutions.
Compensation and Benefits
The company provides competitive salary, benefits:, good working environment, sound training mechanism, broad development platform and clear career development direction.
Available benefits:
Five insurance policies;
Commercial medical insurance;
Paid annual vacation;
Annual free medical checkup;
Meal allowance;
Shuttle;
Employee dormitory;
Holiday and summer vacation expenses;
Beijing Caine is sincerely expecting You, join Kain, you will really get the win-win and **** glory of the staff and the enterprise.
Recruitment Email: zhaopin@kawin.com.cn
Legal Representative: Zhou Desheng
Establishment Date: 2008-08-20
Registered Capital: 121 Million RMB
Region: Beijing
Unified Social Credit Code: 911103026787533566
Business Status: Open
Industry: Scientific Research and Technology Services
Company Type: Limited Company (Taiwan, Hong Kong, Macao and Domestic Joint Venture, Unlisted)
English Name: Beijing Kawin Technology Share- holding Co., Ltd
Personnel Size: 100-499 people
Enterprise Address: Building 3, No. 6, Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, China
Business Scope: Manufacture of Therapeutic Biological Products (Recombinant Human Interferon a2b Injection, Recombinant Human Interferon a2b for injection, Recombinant Human Interferon a2b Vaginal Effervescent Tablets, Pegylated Interferon a-2 Injection, Recombinant Human Interferon a2a Injection), small volume injection, lyophilized powder injection, tablets, hard capsules, granules; import and export of goods, import and export of technology, import and export of agency; technology development, technology consulting, technology transfer, technical services; equipment leasing; property management. (The enterprise on July 28, 2015 (approval date) from domestic enterprises to foreign-invested enterprises. Projects subject to approval by law, after approval by the relevant departments to carry out business activities in accordance with the approved content).